Alpine Immune Sciences is conducting a Phase 1b Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of a new treatment for immune thrombocytopenia (and other autoimmune cytopenias) called Povetacicept (also known as APLN-303). This study is open to adults with persistent or chronic ITP. Povetacicept is a is a dual B cell cytokine antagonist engineered to inhibit BAFF (BLyS) and APRIL which are clinically validated cytokine pathways that play a key role in B cell development, differentiation, and survival. The drug will be provided to participants every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period. Adult participants must have shown failure to at least two previous treatments for ITP, including exposure to a TPO-RA, unless otherwise contraindicated or unavailable to them. Participants must also have a documented platelet count of less than 30,000 µL.

USA, Australia, Austria, Canada, Germany, Italy, Norway, Spain, Turkey, and the United Kingdom

https://www.clinicaltrials.gov/study/NCT05757570?term=%20Povetacicept%20&rank=2

Actively Recruiting